TCRX TScan Therapeutics Inc.

Biotech Analyst Ratings

Latest News

1. 17 May 2022 TScan Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

   WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that management will participate in a virtual fireside chat at the H.C. Wainwright Global Investment Conference that will be available for viewing on Tuesday, May 24, 2022, at 7:00 a.m. ET.
   

   A webcast of the fireside chat will be available on the "Events and Presentations" section of the Company's website at ir.tscan.com. An archived replay of the webcast will be available on the Company's website for 30 days following the event.

   About TScan Therapeutics, Inc.

   TScan…

   View Full Article
2. 12 May 2022 TScan Therapeutics to Host Virtual KOL Event to Discuss its Solid Tumor Program Strategy and Highlights from the ASGCT 25th Annual Meeting

   WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will host a virtual key opinion leader (KOL) event, to discuss highlights from its presentations at the American Society of Gene & Cell Therapy (ASGCT) 25^th Annual Meeting as well as its solid tumor program on Thursday, May 19, 2022, at 4:30 p.m. ET.
   

   The event will provide an in-depth review of the oral and poster presentations related to solid tumor TCR-T therapy candidates, TSC-200-A02 for HPV16, and TSC-204-C07 for MAGE-A1, as well as TScan's approach…

   View Full Article
3. 09 May 2022 TScan Therapeutics Reports First Quarter 2022 Financial Results and Upcoming Anticipated Milestones

   Preclinical data to be presented at the American Society of Gene & Cell Therapy 25^th Annual Meeting; virtual KOL event following the conference
   

   Phase 1 umbrella trial for leukemia program on track to initiate in the first half of 2022

   Ended the first quarter with cash and cash equivalents of $140.8 million, funding operations into 2024

   WALTHAM, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today reported financial results for the first quarter ended March 31, 2022, and noted key upcoming anticipated milestones…

   View Full Article
4. 02 May 2022 TScan Therapeutics Announces Upcoming Presentations at the 25th American Society of Gene and Cell Therapy Annual Meeting

   WALTHAM, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of three abstracts at the upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, being held from May 16-19, 2022, both in Washington D.C. and virtually. Following the meeting, TScan will host a virtual KOL event on Thursday, May 19, 2022, at 4:30 p.m. ET to discuss the presentations and plans for its solid tumor program. Details for joining the live event can be found below.
   

   Poster presentations:

   Title: Discovery of TSC-200-A02: …

   View Full Article
5. 11 April 2022 TScan Therapeutics Appoints Leiden Dworak, CPA, MBA, as Vice President, Finance

   WALTHAM, Mass., April 11, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Leiden Dworak, CPA, MBA, as Vice President, Finance. Mr. Dworak brings to TScan over a decade of experience in financial infrastructure implementation and operations management in early/mid-stage biotech.
   

   "We are pleased to welcome Leiden to TScan at such an exciting time as we advance our lead liquid tumor TCR-T therapy programs focused on the prevention of relapse in patients undergoing HCT into clinical development," said David Southwell…

   View Full Article